Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
1999-10-01
2001-12-11
Fonda, Kathleen Kahler (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S002600, C536S004100, C536S017200, C536S018700
Reexamination Certificate
active
06329344
ABSTRACT:
FIELD OF INVENTION
This invention generally relates to the derivatives of 5,6-dideoxy-&agr;,D-5-epiglucofuranose, 5,6-dideoxy-&agr;,D-5-epiallofuranose, 5,6-dideoxy-&agr;,D-5-epimannofuranoside, 5-deoxy-&agr;,D-lyxofuranoside, 5-deoxy-&agr;,D-xylofuranose, 5-deoxy-&agr;,D-ribofuranose, or 2,3-isopropylidene-&agr;-L-xylo-2-hexulofuranosonic acid and processes for the preparation thereof.
The compounds of this invention are useful, inter-alia, for the inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies, including inflammatory and autoimmune diseases, such as bronchial asthma, rheumatoid arthritis, type I diabetes, multiple sclerosis, allograft rejection, and psoriasis.
This invention also relates to pharmacological compositions containing the compounds of the present invention and the methods of treating such pathologies as listed above.
BACKGROUND OF THE INVENTION
Cell adhesion is a process by which cells associate with each other, migrate towards a specific target localized within the extracellular matrix. Specialized molecules, called cell adhesion molecules (CAMs), mediate these interactions. CAMs have been demonstrated to participate in various cell-cell, cell-extracellular matrix, and platelet-platelet interactions. CAMs influence the leukocytes' adhesion to the vascular endothelium, their transendothelial migration, retention at extravascular sites, and activation of T cells and eosinophils. These processes are central to the pathogenesis of inflammatory and autoimmune diseases. Therefore, CAMs are considered potential targets in treating such disorders.
CAMs can be classified into three groups: integrins, selectins, and the immunoglobulin superfamily. Of these, integrins are key mediators in the adhesive interactions between hemopoietic cells and their microenvironment. They are comprised of alpha-beta heterodimers that integrate signals from the outside to the inside of cells, and vice versa. Integrins can be classified on the basis of the beta subunits they contain. For example, beta-1 integrins comprise the beta-1 subunit noncovalently linked to one of the 10 different alpha subunits.
The alpha-4 beta-1 integrin, also known as VLA
4
(very late activation antigen 4), is a member of the beta-1 integrin family and comprises alpha-4 and beta-1 subunits. VLA
4
interacts with two specific ligands—the vascular cell adhesion molecule (VCAM-1) and the CS1 region of the protein fibronectin. Adhesion mediated by VLA
4
is central to the process of transendothelial migration of leukocytes. Ligation of VLA
4
is followed by gross rearrangement of the cytoskeleton, leading to flattening of cells along the blood vessel wall, followed by expression of specific molecules that digest the endothelial cell wall and diapedesis. Once in the extraluminal region, the interactions of VLA
4
with extracellular fibronectin play a crucial role in the migration of leukocytes to the site of inflammation, T cell proliferation, and expression of cytokines and inflammatory mediators. Additionally, VLA
4
ligation provides co-stimulatory signals to the leukocytes, resulting in enhanced immunoreactivity. Thus, appropriate VLA
4
antagonists would, in theory, ameliorate the immune response through a twofold action-inhibition of T cell recruitment at the site of inflammation and inhibition of co-stimulatory activation of immune cells.
In this respect, inhibitors of VLA
4
interactions have been demonstrated to show beneficial therapeutic effects in several animal models of inflammatory and allergic diseases, including sheep allergic asthma (Abraham et al, J. Clin. Invest. 1994;93:776); arthritis (Wahl et al, J. Clin. Invest. 1994;94:655); experimental allergic encephalomyelitis (Yednock et al, Nature (Lond) 1992;356:63 and Baron et al, J. Exp. Med. 1993;177:57); contact hypersensitivity (Chisolm et al, Eur J. Immunol. 1993;23:682); type I diabetes (Yang et al, Proc. Natl. Acad. Sci. (USA) 1993;90:10494), and inflammatory bowel disease (Podolsky et al, J. Clin. Invest. 1993;92:372).
The CS1 moiety region of fibronectin involved in the interaction with VLA
4
was identified as the tripeptide Leucyl-Aspartyl-Valyl (LDV) (Komoriya et al, J. Biol. Chem. 1991;266:15075). Several peptides containing the LDV sequence were synthesized and also shown to inhibit the in vivo interaction of VLA
4
to its ligands (Ferguson et al, Proc. Natl. Acad. Sci., USA, 1991;88:8072; Wahl et al, J. Clin. Invest. 1994;94:655; Nowlin et al, J. Biol. Chem. 1993;268(27):20352; and PCT application PCT/US91/04862).
Despite these advances, a need for small and specific inhibitors of VLA
4
-dependent cell adhesion molecules remains. Ideally, such inhibitors are water soluble with oral efficacy. Such compounds would provide useful agents for treatment, prevention, or suppression of various inflammatory pathologies mediated by VLA
4
binding.
It is generally known that isopropylidene and benzylidene groups are the most commonly used protective groups in carbohydrate chemistry. Although both these groups are introduced into a molecule under similar conditions, the location of the protection can be quite different. The reason for this difference is directly related to the stability of each protected molecule. Since protection normally occurs under conditions that allow reversibility, the reaction proceeds until equilibrium is reached. The distribution of products at equilibrium is determined by their relative thermodynamic stabilities. In other words, these reactions are thermodynamically controlled. Benzylidene groups prefer to be part of 6-membered ring acetals, while the ketals resulting from acetonation generally are 5-membered rings. The difference is attributed to the effect of the methyl and phenyl substituents on the stability of the particular ring systems. These blocking methods are described in U.S. Pat. Nos. 2,715,121, 4,056,322, 4,735,934, 4,996,195, and 5,010,058, the disclosures of which are incorporated herein by reference. Other blocking methods are also described in J. Carbohydr. Chem., 1985;4:227 and 1984;3:331; Methods in Carbohydr. Chem. 1962;1:191 and 1962;1:107; Can J. Chem. 1984;62:2728, 1969;47:1195, 1455, and 1970;48:1754, all incorporated herein by reference. The prior art reveals that D-glucose is blocked at the 1,2;5,6-positions with isopropylidene or cyclohexylidene blocking group with the 3-position left open to undergo derivatization. The therapeutic activity of hexoses and their derivatives is also disclosed in some of the above-cited prior art.
The compounds of the present invention were screened for inhibitory activity in VLA
4
-mediated cell adhesion assay and the classical murine hypersensitivity assay in mice. Several compounds exhibited significant inhibitory activity in both tests. The salts of these compounds could be easily solubilized in water and used in the treatment of chronic, cell adhesion-mediated, allergic, autoimmune and inflammatory disorders, such as bronchial asthma and rheumatoid arthritis. Some of the prior art describes development of peptide derivatives as cell adhesion antagonists for treatment of these diseases. However, because treatment of chronic diseases requires prolonged (mid-term to long-term) administration of drugs, the development of small molecules, i.e., specific orally-available inhibitors of cell adhesion, would be very beneficial.
There is no example available in the prior art wherein the compounds of the present invention, containing a sugar nucleus coupled with a urea moiety, are used as therapy for the inhibition, prevention, and suppression of VLA
4
-mediated cell adhesion and pathologies associated with that adhesion.
SUMMARY OF THE INVENTION
An object of the present invention is to provide a new class of compounds that exhibit significant activity as VLA
4
antagonists.
Intermediates mentioned in U.S. Pat. Nos. 4,996,195, 5,637,570, 5,367,062, 5,360,794, 5,360,792, 5,298,494 and 5,010,058 were used as core nuclei and prepared similarly as described in these patents. However, in the present application it has been discovered
Arora Sudershan K.
Gupta Jang P.
Sharma Geeta
Tanwar Madan P.
Deshmuhk, Esq. Jayadeep R.
Fonda Kathleen Kahler
Ranbaxy Laboratories Limited
LandOfFree
Derivatives of monosaccharides as cell adhesion inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Derivatives of monosaccharides as cell adhesion inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Derivatives of monosaccharides as cell adhesion inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2574136